Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia

References

• Jelkmann W. Biosimilar epoetins and other “follow-on” biologic s: update on the European experiences. Am JHematol. 2010;85:771–780.
   PubMed Web of Science ®Google Scholar
• Kramer I. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest. 2008;31:479–488.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Follow-on biologics: challenges ofthe “next generation”. Nephrol Dial Transplant. 2005;20 Suppl 4:iv31-iv36.
   Web of Science ®Google Scholar
• Sekhon BS, Saluja V Biosimilars: an overview. Biosimilars. 2011;1:1–11.
   Google Scholar
• Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38:557–566.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, February 22, 2006. Doc Ref EMEA/ CHMP/BMWP/49348/2005. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/4934805en_pdf. Accessed January 31, 2012.
   Google Scholar
• European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, February 22, 2006. Doc Ref EMEA/CHMP/BMWP/42832/2005. Available at: http://www. emea.europa.eu/pdfs/human/biosimilar/4283205en_pdf. Accessed February 1, 2012.
   Google Scholar
• European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Annex to guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. London, February 22, 2006. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/9452805en_pdf. Accessed January 31, 2012.
   Google Scholar
• European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. London, October 30, 2005. Doc Ref CHMP/437/04. Available at: http://www.emea.europa eu/pdfs/human/biosimilar/043704en_pdf. Accessed January 31, 2010.
   Google Scholar
• Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony- stimulating factor in patients. Br J Cancer. 1988;58:64–69.
   PubMed Web of Science ®Google Scholar
• Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809–813.
   PubMed Web of Science ®Google Scholar
• Roberts AW. G-CSF: a key regulator of neutrophil production, but that’s not all! Growth Factors. 2005;23:33–41.
   PubMed Web of Science ®Google Scholar
• Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62 Suppl 1:1–15.
   Google Scholar
• Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72:2074–2081.
   PubMed Web of Science ®Google Scholar
• Gomez RC, Pinto MA, Gonzalez BM. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Transl Oncol. 2006;8:729–734.
   Google Scholar
• Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. J Exp Med. 1987;165:941–948.
   PubMed Web of Science ®Google Scholar
• Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88:1907–1929.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2010;47:8–32.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). Annex to guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. London, February 22, 2006. Doc Ref EMEA/CHMP/BMWP/31329/2005. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/3132905en pdf. Accessed February 1, 2012.
   Google Scholar
• Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphoma. Onkologie. 2009;32:599–604.
   PubMed Web of Science ®Google Scholar
• Gascon P, Fuhr U, Sorgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2009;21:1419–1429.
   Web of Science ®Google Scholar
• Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A Phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010;33:504–511.
   PubMedGoogle Scholar
• Burnett B, Radic Krleza I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. Eur J Hosp Pharm. 2011;17:50–57.
   Google Scholar
• Hammerling U, Kroon R, Sjodin L. In vitro bioassay with enhanced sensitivity for human granulocyte colony-stimulating factor. J Pharm Biomed Anal. 1995;13:9–20.
   PubMed Web of Science ®Google Scholar
• Righetti PG, Verzola B. Folding/unfolding/refolding of proteins: present methodologies in comparison with capillary zone electrophoresis. Electrophoresis. 2001;22:2359–2374.
   Web of Science ®Google Scholar
• Sreerama N, Woody RW. Computation and analysis of protein circular dichroism spectra. Methods Enzymol. 2004;383:318–351.
   PubMed Web of Science ®Google Scholar
• Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:927–933.
   Web of Science ®Google Scholar
• Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, Phase I trial. Ann Hematol. 2010;89:971–978.
   PubMed Web of Science ®Google Scholar
• Sugiura M, Yamamoto K, Sawada Y, Iga T. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF): comparison between intravenous and subcutaneous administration. Biol Pharm Bull. 1997;20:684–689.
   Web of Science ®Google Scholar
• Anderlini P. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol. 2009;16:35–40.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, doubleblind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000;96:80–85.
   PubMed Web of Science ®Google Scholar
• Brugger W, Birken R, Bertz H, et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol. 1993;84:402–407.
   PubMed Web of Science ®Google Scholar
• Chow SC, Tse SK. Outlier detection in bioavailability/bioequivalence studies. Stat Med. 1990;9:549–558.
   PubMed Web of Science ®Google Scholar
• Liao JJ. A new approach for outliers in a bioavailability/bioequivalence study. J Biopharm Stat. 2007;17:393–405.
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev. 1996;28:625–658.
   PubMed Web of Science ®Google Scholar
• del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfil- grastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35.
   PubMed Web of Science ®Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–731.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy- induced febrile neutropenia. J Oncol Pharm Pract. 2012;18:171–179.
   PubMedGoogle Scholar
• European Generic Medicines Association. Biosimilars Handbook. 2nd ed. Brussels, Belgium: European Generic Medicines Association; 2011.
   Google Scholar
• Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Assessing the bioequivalence of biosimilars: the Retacrit case. Drug Discov Today. 2009;14:495–499.
   PubMed Web of Science ®Google Scholar
• Fuhr JP. Biosimilars and follow-on biologics. Expert Rev Pharmacoecon Outcomes Res. 2009;9:149–150.
   Google Scholar
• Genazzani AA, Biggio G, Caputi AP, et al. Biosimilar drugs : concerns and opportunities. Bio Drugs. 2007;21:351–356.
   Google Scholar
• Kresse GB. Biosimilars – science, status, and strategic perspective. Eur J Pharm Biopharm. 2009;72:479–486.
   PubMed Web of Science ®Google Scholar